Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

Recruiting now · Phase 4

Conditions studied: Chikungunya Virus Infection

In brief

Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.

Key facts

Study ID

NCT06928753

Run by

Centre Hospitalier Universitaire de la Réunion

People needed

1800

Starts

2025-04-18

Expected to finish

2026-10-01

Last updated by the study team

2025-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible for anti-chikungunya vaccination according to french Health Authority (HAS)
• Beneficiary of social security coverage
• Signature of informed consent form

You may not qualify if…

• Pregnant women
• Vaccine contraindication for patients undergoing medical treatment
• Persons under guardianship, curatorship or safeguard of justice
• Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration

Where it is running

• CHU La Réunion — Saint-Denis, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.